title: Estrogen receptor alpha polymorphisms and the risk of prostate cancer development.
abstract: OBJECTIVE
  The main purpose of the study was to evaluate the effect of two polymorphisms in the estrogen receptor alpha, rs2077647 and rs3798577, on the development of prostate cancer, their correlation with selected clinical characteristics, as well as consideration of potential interactions between four estrogen receptor alpha polymorphisms (rs2077647, rs3798577, PvuII, XbaI).
  
  
  METHODS
  The study was performed using 395 patients with histologically verified prostate cancer and 253 healthy male controls.
  
  
  RESULTS
  The CC genotype of rs2077647 was significantly associated with prostate cancer (OR = 1.61). No association was found between rs3798577 polymorphism and prostate cancer. After stratification of patients according to the age at diagnosis and Gleason score, we observed significant correlation between rs2077647 polymorphism and prostate cancer risk in patients diagnosed before the age of 60 as well as patients with Gleason score <7, while rs3798577 was significantly associated with prostate cancer risk development in patients older than 60 and with Gleason score ≥7. Double analysis of each combination of four studied polymorphisms showed that presence of at least three variant alleles was associated with prostate cancer risk in all combinations, while each containing rs3798577 was significantly associated with development of high-grade carcinomas.
  
  
  CONCLUSIONS
  The present study suggests that rs2077647 polymorphism may be a risk factor for prostate cancer especially in patients diagnosed before the age of 60, while rs3798577 polymorphism could probably serve rather as promoting factor in combination with other polymorphisms in estrogen receptor alpha contributing preferably to development of high-grade carcinomas.
authors.affiliation: Department of Medical Biochemistry, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovak Republic. jurecekova@jfmed.uniba.sk.
authors.forename: Jana
authors.initials: J
authors.lastname: Jurečeková
authors.affiliation: Department of Medical Biochemistry, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovak Republic.
authors.forename: Eva
authors.initials: E
authors.lastname: Babušíková
authors.affiliation: Department of Medical Biochemistry, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovak Republic.
authors.forename: Monika
authors.initials: M
authors.lastname: Kmeťová
authors.affiliation: Department of Urology, Jessenius Faculty of Medicine and University Hospital Martin, Comenius University in Bratislava, Martin, Slovak Republic.
authors.forename: Ján
authors.initials: J
authors.lastname: Kliment
authors.affiliation: Department of Medical Biochemistry, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovak Republic.
authors.forename: Dušan
authors.initials: D
authors.lastname: Dobrota
mesh_terms: D000368:Aged; D016022:Case-Control Studies; D047628:Estrogen Receptor alpha / Q000235:genetics*; D005787:Gene Frequency / Q000235:genetics; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D011471:Prostatic Neoplasms / Q000453:epidemiology* / Q000235:genetics*; D012306:Risk; D012307:Risk Factors
chemical_list: C506487:ESR1 protein, human; D047628:Estrogen Receptor alpha
keywords: Estrogen receptor alpha; Gene; Polymorphism; Prostate cancer
references.citation: Mol Carcinog. 2003 Aug;37(4):202-8
references.pmid: 12891629
references.citation: Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2543-8
references.pmid: 15699342
references.citation: Mol Endocrinol. 2005 Aug;19(8):1951-9
references.pmid: 15705661
references.citation: Prostate. 1995 Dec;27(6):304-13
references.pmid: 7501542
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):243-7
references.pmid: 11895872
references.citation: Breast Cancer Res Treat. 2010 May;121(1):177-84
references.pmid: 19760036
references.citation: Mol Cell Endocrinol. 2012 Jan 30;348(2):440-9
references.pmid: 21925568
references.citation: Ageing Res Rev. 2002 Feb;1(1):17-28
references.pmid: 12039446
references.citation: Eur Urol. 2009 Mar;55(3):533-42
references.pmid: 19013008
references.citation: J Urol. 2006 Feb;175(2):523-7
references.pmid: 16406987
references.citation: Anticancer Res. 2004 Jul-Aug;24(4):2431-7
references.pmid: 15330195
references.citation: Endocr Relat Cancer. 2003 Jun;10(2):187-91
references.pmid: 12790781
references.citation: Mol Carcinog. 2012 Oct;51 Suppl 1:E104-17
references.pmid: 22228197
references.citation: OMICS. 2011 Jun;15(6):369-74
references.pmid: 21348640
references.citation: Prostate. 2013 Jan;73(1):1-10
references.pmid: 22549291
references.citation: Science. 1988 May 13;240(4854):889-95
references.pmid: 3283939
references.citation: Am J Pathol. 2001 Jul;159(1):79-92
references.pmid: 11438457
references.citation: PLoS One. 2009 Aug 05;4(8):e6523
references.pmid: 19654868
references.citation: J Endocrinol. 2001 Mar;168(3):447-54
references.pmid: 11241176
references.citation: Prostate. 2012 Jun 15;72(9):1013-22
references.pmid: 22025007
references.citation: Mol Cell Biochem. 2013 Sep;381(1-2):201-7
references.pmid: 23737135
references.citation: EMBO J. 1988 Nov;7(11):3385-8
references.pmid: 3145193
references.citation: Genomics. 1993 Jul;17(1):263-5
references.pmid: 8406468
references.citation: Eur Urol. 2003 Oct;44(4):487-90
references.pmid: 14499686
references.citation: Breast Cancer Res Treat. 2008 Apr;108(3):351-61
references.pmid: 17592774
references.citation: J Clin Endocrinol Metab. 2011 Feb;96(2):E368-72
references.pmid: 21106711
references.citation: Pathol Oncol Res. 2010 Dec;16(4):485-96
references.pmid: 20383761